A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 349 participants.

Also called NCT06184568

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 349 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06184568
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06184568. Randomized; no masking; primary purpose treatment. Start 2024-02-29 (actual); primary completion 2025-09-17 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity
Condition
Obesity
Intervention (Drug)
IBI362
Intervention (Drug)
Semaglutide
Lead sponsor
Innovent Biologics (Suzhou) Co. Ltd. (class: industry)

Record details

Record id
cardio:ct-nct06184568
Content hash
889459636c07018dc9856d356614452977069f0494a28bb095ab101da39f52a2